<DOC>
	<DOC>NCT00086034</DOC>
	<brief_summary>The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.</brief_summary>
	<brief_title>Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<criteria>≥ 18 years old Refractory or relapsed indolent NHL. Eligible WHO histologies include follicular NHL (Grades 1, 2, and 3); marginal zone nodal; marginal zone splenic; and mucosaassociated lymphoid tissue (MALT) types Failed ≥ 1 previous regimens, one of which must have contained rituximab as either a single agent or in combination with chemotherapy ECOG performance status score either 0 or 1 Willing and able to provide written informed consent Laboratory values of: Platelet count &lt; 50,000/µL AST or ALT &gt; 2 x the upper limit of normal (ULN) Total bilirubin &gt; 2 x ULN Creatinine &gt; 2.0 mg/dL and Greater than three prior regimens (where a regimen is defined as a treatment for NHL given after disease progression) Uncontrolled hypertension Known history of porphyria, G6PD deficiency, HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Non-Hodgkin's Lymphoma</keyword>
	<keyword>Indolent lymphoma</keyword>
	<keyword>Relapsed lymphoma</keyword>
	<keyword>Refractory lymphoma</keyword>
	<keyword>Motexafin gadolinium</keyword>
</DOC>